Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02867033 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

National Clinical-biological Prospective Cohort of Incident Cases of Aggressive Fibromatosis (ALTITUDES)

Study acronym: ALTITUDES
StatusActive, Not Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Secondary endpoints: 7 to 8v11
  2. Study completion date: Nov 2031 to Nov 2030v10
  3. Study sites: 38 to 39
    • Collaborators: 3 to 7
    v9
  4. Primary completion date: Mar 2025 to Nov 2030
    • Study completion date: Mar 2026 to Nov 2031
    v8
  5. Re-verified, no change to tracked fieldsv7
Show 5 earlier versionsHide 5 earlier versions
  1. Primary endpoint revised
    • Enrollment target: 630 to 628
    • Secondary endpoints: 5 to 7
    • Eligibility criteria expanded, about 3 words
    v6
  2. Primary completion date: Feb 2022 to Mar 2025v5 Show 5 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 600 to confirmed 630
    • Study sites: 39 to 38
    • Study completion date: Aug 2022 to Mar 2026
    • Start date: Mar 2016 to Mar 22, 2016
  3. Primary completion date: Jun 2021 to Feb 2022
    • Study completion date: Dec 2021 to Aug 2022
    • Site details revised at 7 of 39 sites
    v4
  4. Study sites: 34 to 39v3
  5. Secondary endpoints: 4 to 5v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to constitute the French largest Aggressive fibromatosis cohort.
Trial Details
NCT Number NCT02867033
Lead Sponsor Centre Oscar Lambret
Collaborators: Ligue contre le cancer, France, Institut Curie, Hôpital de la Timone, SOS Desmoid e.V., APICIL funding, Groupement Interrégional de Recherche Clinique et d'Innovation, UNICANCER
Conditions
(from sponsor)		 Aggressive Fibromatosis
Related terms Desmoid Tumors
Enrollment 628 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov